Clinical efficacy of dirithromycin in patients with bacteremic pneumonia

Clinical Therapeutics

Volumn 18, Issue 6, 1996, Pages 1128-1138

  Hernández, Jesús M ^a   Sides, Gregory D ^b   Conforti, Paul M ^b   Smietana, Maria G ^b  

^a Department of Medical Research   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIRITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0030483549     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80067-1     Document Type: Article

References (33)

1. Antela A, Guerrero A, Meseguer M, et al. Community acquired pneumonia: A prospective study of 101 adult immunocompetent patients. Enferm Infecc Microbiol Clin. 1993;11:13-18.
2. Blanquer J, Blanquer R, Borrás R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: A multicenter prospective study. Thorax. 1991;46:508-511.
3. Marrie TJ. Bacteraemic pneumococcal pneumonia: A continuously evolving disease. J Infect. 1992;24:247-255.
4. Bachmann K, Jauregui L, Sides G, et al. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol. 1993;33: 861-865.
5. Bachmann K, Nunlee M, Martin M, et al. Changes in steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J Clin Pharmacol. 1990;30: 1001-1005.
6. Bachmann K, Sullivan TJ, Reese JH, et al. The influence of dirithromycin on the pharmacokinetics of cyclosporine in healthy subjects and in renal patients. Am J Therap. 1995;2:490-498.
7. Ellsworth A, Horn JR, Wilkinson W, et al. An evaluation of the effect of dirithromycin (D) and erythromycin (E) on the pharmacokinetics of warfarin (W). In: Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, Calif: American Society for Microbiology; 1995:19. Abstract no. A44.
8. Goldberg MJ, DeSante K, Cerimele B, et al. Effect of dirithromycin on terfenadine pharmacokinetics and QTc in healthy men. Presented at the American Society for Clinical Pharmacology and Therapeutics, March 1995. Abstract.
9. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother. 1993;37:265-269.
10. Nightingale SL. From the Food and Drug Administration: Warnings issued on non-sedating antihistamines terfenadine and astemizole. JAMA. 1992;268:705.
11. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. din Pharmacokinet. 1992;23:106-131.
12. Wermeling DP, Chandler MHH, Sides G, et al. Dirithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstet Gynecol. 1995;86:78-84.
13. Counter FT, Ensminger PW, Preston DA, et al. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother. 1991;35:1116-1126.
14. Dilorenzo P, Shupbach C, Salisbury J, et al. Dirithromycin 5 days versus erythromycin base 7 days in skin and soft tissue infections. In: Program and Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology: 1993:192. Abstract no. 402.
15. Lode H, Smits JPH. Clinical efficacy of dirithromycin versus roxithromycin in acute bacterial exacerbation of chronic bronchitis. In: Program and Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1993:192. Abstract no. 401.
16. Salisbury J, Chiulli R, Taylor J, et al. Dirithromycin 5 days versus erythromycin 7 days in acute superimposed on chronic bronchitis. In: Program and Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1993:192. Abstract no. 400.
17. Sides GD, Cerimele BJ, Black HR, et al. Pharmacokinetics of dirithromycin. J Antimicrob Chemother. 1993;31(Suppl C): 65-75.
18. Huck W, Guthrie EH, Smits P, et al. Dirithromycin versus erythromycin base in lobar pneumonia/bronchopneumonia, or pneumonia due to mycoplasma, legionella or chlamydia infection. In: Program and Abstracts of the 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1992:391. Abstract no. 1680.
19. Jacobson K. Clinical efficacy of dirithromycin in pneumonia. J Antimicrob Chemother. 1993;31(Suppl C):121-129.
20. Derriennic M, Conforti PM, Sides GD. Dirithromycin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother. 1993;31(Suppl C):89-95.
21. Müller O, Wettich K. Clinical efficacy of dirithromycin in pharyngitis and tonsillitis. J Antimicrob Chemother. 1993;31 (Suppl C):97-102.
22. Derriennic M, Escande JP. Dirithromycin in the treatment of skin and skin structure infections. J Antimicrob Chemother. 1993; 31(Suppl C):159-168.
23. Gaillat J. A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of bronchitis. J Antimicrob Chemother. 1993; 31(Suppl C):139-151.
24. Sides GD. Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1993; 31(Suppl C):131-138.
25. Bergogne-Bérézin E. Tissue distribution of dirithromycin: Comparison with erythromycin. J Antimicrob Chemother. 1993; 31(Suppl C):77-87.
26. Cazzola M, Matera MG, Tufano MA, et al. Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. Pulm Pharmacol. 1994;7:377-381.
27. Labro MT, M'Tairag M. Antibacterial synergy between dirithromycin, erythromycylamine and roxithromycin and neutrophils. In: Program and Abstracts of the 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1992:395. Abstract no. 1705.
28. Labro MT, el Benna J, Abdelghaffar H. Modulation of human polymorphonuclear neutrophil function by macrolides: Preliminary data concerning dirithromycin. J Antimicrob Chemother. 1993;31(Suppl C):51-64.
29. McDonald PJ, Pruul H. Macrolides and the immune system. Scand J Infect Dis. 1992;(Suppl 83):34-40.
30. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
31. García-Leoni ME, Moreno S, Rodeno P, et al. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med. 1992;152:1808-1812.
32. Janoff E, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives, Ann Intern Med. 1992;117:314-324.
33. Klenerman P, Luzzi GA, Peto TEA. Pneumococcal disease and HIV infection. Ann Intern Med. 1993;118:393-394. Letter.